aplastic anemia
Information
- Disease name
- aplastic anemia
- Disease ID
- DOID:12449
- Description
- "A normocytic anemia that is characterized by a deficiency of red blood cells, white blood cells and platelets produced by bone marrow." [url:http\://en.wikipedia.org/wiki/Aplastic_anemia, url:http\://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06039020 | Active, not recruiting | ATGAM General Investigation | February 21, 2024 | February 13, 2026 | |
| NCT03025698 | Active, not recruiting | Phase 2 | A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia | September 30, 2017 | January 29, 2025 |
| NCT01659606 | Active, not recruiting | Phase 2 | Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | July 2012 | December 2034 |
| NCT04558736 | Active, not recruiting | Phase 2 | Haploidentical HCT for Severe Aplastic Anemia | January 21, 2021 | July 1, 2026 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT04478227 | Active, not recruiting | Early Phase 1 | TPO-Mimetic Use in Children for Hematopoietic Failure | August 18, 2020 | June 2024 |
| NCT02566304 | Active, not recruiting | Phase 2 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | November 13, 2015 | February 13, 2024 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT00053989 | Completed | Phase 2 | NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders | January 29, 2002 | July 19, 2018 |
| NCT00065260 | Completed | Phase 2 | Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia | November 6, 2003 | February 5, 2016 |
| NCT00186797 | Completed | N/A | Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia | December 2002 | May 2007 |
| NCT00343785 | Completed | Phase 2 | Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant | February 2006 | August 2012 |
| NCT00427336 | Completed | N/A | Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia | December 2000 | August 2009 |
| NCT00455312 | Completed | Phase 2/Phase 3 | Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA | August 2007 | June 2016 |
| NCT00471848 | Completed | Phase 2 | Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia | August 2008 | February 2013 |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT00533923 | Completed | Phase 2 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | December 2002 | January 2007 |
| NCT00569842 | Completed | Investigation of the Cylex® ImmuKnow® Assay | November 2007 | December 2012 | |
| NCT00636909 | Completed | Phase 2 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | July 1999 | |
| NCT00673114 | Completed | Phase 1/Phase 2 | Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies | August 2007 | April 2012 |
| NCT00767650 | Completed | Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia | September 23, 2008 | June 28, 2011 | |
| NCT00806598 | Completed | Phase 2 | Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome | May 2005 | June 2012 |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT02875743 | Completed | Phase 4 | King's Invasive Aspergillosis Study II | December 7, 2016 | October 31, 2019 |
| NCT00004474 | Completed | Phase 3 | Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia | September 1998 | August 2007 |
| NCT03208647 | Completed | Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia | January 1, 2003 | January 1, 2014 | |
| NCT03176849 | Completed | Phase 4 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | November 1, 2017 | July 1, 2019 |
| NCT00005935 | Completed | Phase 2 | Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia | June 2000 | March 2002 |
| NCT00006300 | Completed | Oral Manifestations of Aplastic Anemia | April 2000 | April 2002 | |
| NCT00011453 | Completed | Protection Against Benzene Toxicity | July 1998 | June 2001 | |
| NCT00011830 | Completed | Phase 1 | Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission | February 2001 | February 2006 |
| NCT02094417 | Completed | Phase 2 | A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia | April 14, 2014 | November 7, 2017 |
| NCT00004464 | Completed | Phase 2 | Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria | February 1996 | November 11, 2008 |
| NCT03896971 | Completed | Phase 4 | Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia | November 15, 2019 | June 1, 2021 |
| NCT02225145 | Completed | Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease | August 15, 2014 | September 20, 2017 | |
| NCT02404025 | Completed | Phase 2 | Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects | May 12, 2015 | September 6, 2017 |
| NCT02462252 | Completed | Phase 2 | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | October 2015 | November 2020 |
| NCT02773290 | Completed | Phase 2/Phase 3 | Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia | May 2016 | July 28, 2020 |
| NCT02833805 | Completed | Phase 2 | NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia | September 2016 | July 2021 |
| NCT03318159 | Completed | Phase 2 | Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | April 20, 2018 | July 15, 2023 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT00987480 | Completed | Phase 2 | Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine | September 25, 2009 | July 10, 2017 |
| NCT01105273 | Completed | Phase 1/Phase 2 | Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia | July 2009 | July 2012 |
| NCT01187017 | Completed | Phase 1/Phase 2 | A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia | August 2010 | July 2012 |
| NCT01193283 | Completed | Phase 1/Phase 2 | Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia | August 2010 | September 2014 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231841 | Completed | Phase 2 | Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia | March 2005 | December 2010 |
| NCT01241357 | Completed | High-Tc Susceptometer to Monitor Transfusional Iron Overload | March 2011 | May 2016 | |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01297972 | Completed | Phase 1/Phase 2 | Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia | February 2011 | November 2013 |
| NCT01350245 | Completed | Phase 2 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | July 2010 | May 2014 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT04439006 | Completed | Phase 1 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | October 23, 2020 | September 20, 2022 |
| NCT01441037 | Completed | Phase 1/Phase 2 | Danazol for Genetic Bone Marrow and Lung Disorders | July 19, 2011 | November 14, 2016 |
| NCT01499147 | Completed | N/A | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | February 2000 | May 2013 |
| NCT04403321 | Completed | Phase 2 | Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients | July 1, 2020 | July 31, 2022 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT00001398 | Completed | Phase 1 | Stem Cell Factor Medication for Aplastic Anemia | October 1993 | June 2002 |
| NCT04350606 | Completed | Phase 3 | A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia | July 25, 2020 | April 19, 2021 |
| NCT00004323 | Completed | Phase 2 | Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia | February 1995 | |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT04128943 | Completed | Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria | November 1, 2019 | July 6, 2020 | |
| NCT04095936 | Completed | Phase 2/Phase 3 | Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia | December 3, 2019 | October 29, 2021 |
| NCT01956799 | Completed | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | May 2013 | December 2019 | |
| NCT03988608 | Completed | Phase 2 | Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. | December 9, 2019 | May 17, 2023 |
| NCT03957694 | Completed | Phase 2/Phase 3 | Study of AMG531(Romiplostim) in Patients With Aplastic Anemia | April 25, 2019 | May 26, 2021 |
| NCT02055456 | Completed | Phase 1/Phase 2 | Nandrolone Decanoate in the Treatment of Telomeropathies | February 1, 2014 | February 1, 2017 |
| NCT04870346 | Enrolling by invitation | Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia | May 10, 2021 | June 30, 2024 | |
| NCT03906318 | No longer available | Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia | |||
| NCT05399732 | Not yet recruiting | Phase 2 | Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia | July 2022 | July 2024 |
| NCT05333861 | Not yet recruiting | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | May 1, 2022 | May 1, 2026 | |
| NCT06004791 | Not yet recruiting | Phase 4 | A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA | August 2023 | August 31, 2025 |
| NCT06287268 | Not yet recruiting | Revolade Tablets Specified Drug-use Survey | June 28, 2024 | October 31, 2028 | |
| NCT06398457 | Not yet recruiting | Early Phase 1 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | June 2024 | December 2026 |
| NCT05996393 | Not yet recruiting | Phase 4 | CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly | October 2023 | October 2026 |
| NCT06426043 | Not yet recruiting | Phase 4 | A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag | June 2024 | August 2025 |
| NCT06424639 | Not yet recruiting | Phase 4 | Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA | May 2024 | December 2025 |
| NCT06430788 | Recruiting | Phase 2 | A Study of Emapalumab for Pediatric Aplastic Anemia | May 21, 2024 | May 21, 2029 |
| NCT01624805 | Recruiting | Phase 2 | Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome | June 25, 2012 | June 30, 2026 |
| NCT01758042 | Recruiting | N/A | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders | November 2012 | July 2027 |
| NCT02162420 | Recruiting | N/A | Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia | January 10, 2015 | July 2026 |
| NCT03016806 | Recruiting | Phase 1 | Umbilical Cord Blood Transplantation From Unrelated Donors | June 2015 | June 2026 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT04060485 | Recruiting | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | August 19, 2019 | December 31, 2024 | |
| NCT04645199 | Recruiting | National Longitudinal Cohort of Hematological Diseases | December 1, 2020 | December 1, 2030 | |
| NCT04761965 | Recruiting | N/A | Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy | February 16, 2021 | January 1, 2024 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05194397 | Recruiting | Phase 2 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors | March 21, 2023 | June 30, 2026 |
| NCT05386264 | Recruiting | Phase 1 | Autologous Tregs for Aplastic Anaemia | July 14, 2022 | April 30, 2025 |
| NCT05510505 | Recruiting | Phase 2 | GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT | December 30, 2021 | December 2025 |
| NCT05571332 | Recruiting | N/A | Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function | June 28, 2022 | June 28, 2024 |
| NCT05832216 | Recruiting | Phase 1 | Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia | April 17, 2023 | December 31, 2026 |
| NCT06004752 | Recruiting | Phase 2 | Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly | August 17, 2023 | August 2025 |
| NCT06009965 | Recruiting | Phase 4 | Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System | January 20, 2023 | January 31, 2025 |
| NCT06335277 | Recruiting | Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology | February 22, 2018 | December 31, 2024 | |
| NCT00038779 | Terminated | N/A | Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States | August 14, 1996 | September 20, 2004 |
| NCT00001962 | Terminated | Phase 2 | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure | November 1999 | September 2010 |
| NCT01267643 | Terminated | Phase 1 | Alefacept in Patients With Relapsed/Refractory Aplastic Anemia | May 2011 | April 16, 2013 |
| NCT01343680 | Terminated | Phase 3 | Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients | April 2011 | May 2012 |
| NCT00676806 | Terminated | Phase 2 | A Phase II Study of Umbilical Cord Blood Transplantation | July 2005 | July 2014 |
| NCT01818726 | Terminated | Phase 4 | Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients | June 23, 2014 | October 17, 2016 |
| NCT00354419 | Terminated | Phase 1 | Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant | February 2006 | |
| NCT00578903 | Terminated | Phase 2 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | February 2002 | July 2012 |
| NCT01500161 | Terminated | Phase 2 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | November 2011 | November 2013 |
| NCT00556400 | Terminated | Phase 1/Phase 2 | Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones | November 2007 | June 2012 |
| NCT04001686 | Unknown status | Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain | January 31, 2018 | September 30, 2022 | |
| NCT01919866 | Unknown status | Phase 1/Phase 2 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | March 2004 | December 2015 |
| NCT01305694 | Unknown status | Phase 1/Phase 2 | Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. | February 2011 | December 2012 |
| NCT00881933 | Unknown status | Phase 1/Phase 2 | Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA) | November 2008 | September 2012 |
| NCT04728789 | Unknown status | Phase 2/Phase 3 | Avatrombopag Usage in NSAA | February 1, 2021 | June 30, 2023 |
| NCT04819607 | Unknown status | The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders. | June 9, 2021 | April 2024 | |
| NCT05018936 | Unknown status | Phase 2/Phase 3 | Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia | October 1, 2021 | December 1, 2023 |
| NCT00017654 | Unknown status | N/A | Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia | April 2001 | |
| NCT01182662 | Unknown status | Phase 2 | Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia | August 2010 | August 2013 |
| NCT01145976 | Unknown status | Phase 3 | Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia | March 2010 | February 2016 |
| NCT02007811 | Unknown status | Phase 1/Phase 2 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | November 2013 | December 2015 |
| NCT01995331 | Unknown status | Phase 4 | Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia | March 2012 | March 2015 |
| NCT00882323 | Unknown status | Phase 2 | Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) | November 2008 | October 2012 |
| NCT03055078 | Unknown status | Phase 1 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia | January 2017 | December 2019 |
| NCT03218657 | Unknown status | N/A | Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole | January 1, 2018 | July 1, 2022 |
| NCT02838992 | Unknown status | Phase 4 | ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia | February 2017 | July 2019 |
| NCT02833493 | Unknown status | Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload | September 2016 | October 2019 | |
| NCT03373526 | Unknown status | N/A | Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation | November 11, 2017 | December 31, 2019 |
| NCT03821987 | Unknown status | N/A | Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA | December 17, 2018 | March 30, 2022 |
| NCT02203396 | Unknown status | Phase 2 | A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia | August 2014 | September 2017 |
| NCT02028416 | Unknown status | N/A | Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia | September 2013 | December 2017 |
| NCT01408342 | Withdrawn | N/A | Alemtuzumab and Rituximab in Aplastic Anemia | July 2011 | January 2014 |
| NCT03086252 | Withdrawn | N/A | Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study | July 24, 2017 | May 31, 2018 |
| NCT01680055 | Withdrawn | Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors | February 2009 | November 2012 |
- Disase is a (Disease Ontology)
- DOID:720
- Cross Reference ID (Disease Ontology)
- GARD:5836
- Cross Reference ID (Disease Ontology)
- ICD10CM:D61.9
- Cross Reference ID (Disease Ontology)
- ICD9CM:284.9
- Cross Reference ID (Disease Ontology)
- MESH:D000741
- Cross Reference ID (Disease Ontology)
- MIM:609135
- Cross Reference ID (Disease Ontology)
- NCI:C2870
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154807001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0002874
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0001915